TY - JOUR
T1 - Lung infections after cancer chemotherapy
AU - Vento, Sandro
AU - Cainelli, Francesca
AU - Temesgen, Zelalem
PY - 2008/10
Y1 - 2008/10
N2 - Lung infections can be severe consequences of chemotherapy-induced immune defects. Aetiological causes of infection include bacteria (most commonly Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Nocardia species), viruses (eg, respiratory syncytial virus, parainfluenza virus, influenza virus A and B, and cytomegalovirus), and fungi (eg, Aspergillus, Fusarium, and Mucorales species, and Pneumocystis jirovecii). Most infections are caused by bacteria (especially Gram negative), but viruses are being increasingly identified. Diagnosis is difficult and frequently time-consuming. Treatment can be ineffective for many patients, particularly those with fungal infection. The greatest hope for the future is the availability of more targeted anticancer drugs that have fewer side-effects on the immune system.
AB - Lung infections can be severe consequences of chemotherapy-induced immune defects. Aetiological causes of infection include bacteria (most commonly Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Nocardia species), viruses (eg, respiratory syncytial virus, parainfluenza virus, influenza virus A and B, and cytomegalovirus), and fungi (eg, Aspergillus, Fusarium, and Mucorales species, and Pneumocystis jirovecii). Most infections are caused by bacteria (especially Gram negative), but viruses are being increasingly identified. Diagnosis is difficult and frequently time-consuming. Treatment can be ineffective for many patients, particularly those with fungal infection. The greatest hope for the future is the availability of more targeted anticancer drugs that have fewer side-effects on the immune system.
UR - http://www.scopus.com/inward/record.url?scp=52749096517&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=52749096517&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(08)70255-9
DO - 10.1016/S1470-2045(08)70255-9
M3 - Review article
C2 - 19071255
AN - SCOPUS:52749096517
SN - 1470-2045
VL - 9
SP - 982
EP - 992
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 10
ER -